Home  
  Our Team  
  Patient Info  
  Services  
   
  Pay My Bill  
  Contact Us  

News for Healthier Living

Castle Biosciences' DecisionDx(r)-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented a

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31 in Denver, demonstrating that its DecisionDx-Melanoma test refines mortality risk within AJCC stages for patients with cutaneous melanoma (CM).

March 27, 2026


March 27 2026

March 26 2026

March 25 2026

March 24 2026

March 23 2026

March 22 2026

March 21 2026

March 20 2026

March 19 2026

March 18 2026

March 17 2026

March 16 2026

March 15 2026

March 14 2026

March 13 2026